ClinicalTrials.gg
RecruitingNCT07515326CANDYUpdated Apr 7, 2026

Evolution of Clinical and Motivational Constructs During the Physical Activity Program KHEOPS, Already Offered to Patients at the Centre Léon Bérard

An observational study in Breast Cancer, sponsored by Centre Leon Berard. Recruiting at 1 site in France. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-04-07.

Sponsored by Centre Leon Berard · Observational

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
80
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 23 studies in Breast Neoplasms by Centre Leon Berard — 5 open to participants now, 8 under way, none of them phase 3. Breast Neoplasms · Centre Leon Berard.

Started
2024
the only one that year
Observational
7 of 23
4 open now
Registered
21st of 23
by date

Among the 23 studies in Breast Neoplasms by Centre Leon Berard, this one is the only one that started in 2024, is one of 7 observational ones, and was the 21st registered.

Breast Neoplasms

14,848 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

5 of the 23 studies in Breast Neoplasms by Centre Leon Berard are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 23 studies in Breast Neoplasms by Centre Leon Berard, or all of them as a file.
02

Study summary

CANDY is a single-center, prospective study designed to observe the evolution of clinical and motivational constructs during the APA program KHEOPS program, already offered to patients at the Centre Léon Bérard (CLB).

The main aim of the CANDY study is to observe the evolution of psychological constructs derived from M-PAC during a 13-week KHEOPS APA program in women undergoing treatment for breast cancer.

Secondary objectives are:

  • to examine the feasibility of psychological measures and participation in the KHEOPS program
  • to observe cancer-related psychological symptoms during the KHEOPS program and to investigate the links between the temporal evolution of psychological factors (clinical and motivational) and adherence to the KHEOPS program, as well as the level of post-program PA during and after the KHEOPS program in patients followed at the CLB.
03

Conditions studied

  • Breast Cancer

Browse trials for

Keywords

  • Breast cancer
  • physical activty
  • KHEOPS program
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients with breast cancer, with a current treatment, followed at CLB

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Woman aged ≥ 18 years
  • Diagnosed with non- breast cancer
  • Undergoing treatment or after surgery
  • Participating in the CLB KHEOPS program, either face-to-face or distance learning
  • Have a smartphone, computer or tablet to answer the 2 weekly online weekly online questionnaires and to follow APA sessions for patients following the patients following the KHEOPS program remotely
  • Having received a study information note and having made a declaration of non-opposition
  • Affiliated with a social security scheme
  • Able to read, write and understand French

Exclusion criteria

Exclusion Criteria:

  • Unable to be followed for medical, social, family, geographical or psychological reasons, for the duration of the study.
  • Have difficulty completing a questionnaire alone
  • Deprived of liberty by judicial or administrative decision, or adults protected by law
  • Concurrently participating in another PA study
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
80 participants (estimated)
Patient registry
No

Groups and cohorts

  • KHEOPS participants during breast cancer treatment

    Behavioral: KHEOPS program

Interventions

  • BehavioralKHEOPS program

    the KHEOPS program is an physical activity intervention, offered to patients

06

What researchers measure

Primary outcomes

  1. score for each construct of multiprocess action control model (M-PAC)

    * The score for each M-PAC construct oriented toward participation in PA sessions throughout the KHEOPS program; * The score for each M-PAC construct oriented towards PA practice after the KHEOPS program program during the intervention. Constructs of M-PAC : * Attitude towards Physical Activity - Affective Attitude (7-point Likert Scale, extremely disagree to extremely agree) * Attitude towards Physical Activity - Instrumental Attitude (7-point Likert Scale, extremely disagree to extremely agree) * Perceived Capability over Physical Activity (5-point Likert Scale, strongly disagree to strongly agree) * Perceived Opportunity for Physical Activity (5-point Likert Scale, strongly disagree to strongly agree)

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), one friday per month (Friday week 1 to Friday week 22), post-intervention + 1 month (Week 26)

Secondary outcomes

  1. acceptability

    participation rate (\>70%) and dropout rate (\<20%)

    Time frame: Post-intervention (week 22)

  2. completion rate of bi-weekly online questionnaires during the intervention

    (\>80%)

    Time frame: each monday (Monday week 1 to monday week 22), one friday per month (Friday week 1 to friday week 22)

  3. cancer-related psychological symptoms during and after the program

    \- depressive symptoms, by Patient Health Questionnaire

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  4. cancer-related psychological symptoms during and after the program

    \- anxiety symptoms, by Generalized Anxiety Disorder

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  5. cancer-related psychological symptoms during and after the program

    \- perceived pain, by Brief Pain Inventory

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  6. cancer-related psychological symptoms during and after the program

    \- perceived fatigue, by Multidimensional Fatigue Inventory Short Form or Daily Fatigue Cancer Scale

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  7. cancer-related psychological symptoms during and after the program

    \- sense of self-efficacy, by Perceived Capacity over Physical Activity questionnaire

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  8. cancer-related psychological symptoms during and after the program

    \- sense of self-efficacy related to coping with barriers, by Coping self-efficacy Scale

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  9. cancer-related psychological symptoms during and after the program

    \- affective and instrumental attitudes, by Attitude toward PA - affective attitude and instrumental attitude

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  10. cancer-related psychological symptoms during and after the program

    \- habit, by Self-Report Behavioral Automaticity Index

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  11. cancer-related psychological symptoms during and after the program

    \- identity, by Athletic Identity Measurement Scale

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  12. cancer-related psychological symptoms during and after the program

    \- planification, by self-reported planning for PA Scale

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

  13. cancer-related psychological symptoms during and after the program

    \- therapeutic alliance questionnaire, by Therapeutic alliance questionnaire

    Time frame: Inclusion (Day 0), each monday (Monday week 1 to Monday week 22), each friday (Friday week 1 to Friday week 22), post-intervention (week 22), post-intervention + 1 month (Week 26)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Sep 2026, 21 months after the start.

Of 1,193 non-industry observational studies under Breast Neoplasms, half reached primary completion within 58 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 139. This study's planned 21 months is below that.

Counting every sponsor, half of 1,382 studies reached it within 55 months; a quarter within 25 and three quarters within 126.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2025
First posted
Apr 7, 2026
StartActual
Dec 18, 2024
Primary completionEst.
Sep 30, 2026
CompletionEst.
Sep 30, 2026
Last update
Apr 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07515326
Lead sponsor
Centre Leon Berard
Collaborators
Cancéropôle Lyon Auvergne Rhône-Alpes
Responsible party
Sponsor
First posted
Apr 7, 2026
Start date
Dec 18, 2024
Primary completion
Sep 30, 2026 (estimated)
Completion
Sep 30, 2026 (estimated)
Last update
Apr 7, 2026

Study contacts

Carmen Dupuis, PhD
Contact
carmen.dupuisl@lyon.unicancer.fr
0469856218
Olivia Perol, PhD
study director · Département Prévention Cancer Environnement, Centre Léon Bérard
Béatrice Fervers, Pr
principal investigator · Département Prévention Cancer Environnement, Centre Léon Bérard
Johan Caudroit, PhD
study director · Université Lyon1

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion